FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155681330> ?p ?o ?g. }

• W2155681330 abstract "The National Institutes of Health (NIH) estimates that stroke costs now exceed 45 billion dollars per year. Stroke is the third leading cause of death and one of the leading causes of adult disability in North America, Europe, and Asia. A number of well-designed randomized stroke trials and case series have now been reported in the literature to evaluate the safety and efficacy of thrombolytic therapy for the treatment of acute ischemic stroke. These stroke trials have included intravenous studies, intra-arterial studies, and combinations of both, as well as use of mechanical devices for removal of thromboemboli and of neuroprotectant drugs, alone or in combination with thrombolytic therapy. At this time, the only therapy demonstrated to improve outcomes from an acute stroke is thrombolysis of the clot responsible for the ischemic event. There is room for improvement in stroke lysis studies. Divergent criteria, with disparate reporting standards and definitions, have made direct comparisons between stroke trials difficult to compare and contrast in terms of overall patient outcomes and efficacy of treatment. There is a need for more uniform definitions of multiple variables such as collateral flow, degree of recanalization, assessment of perfusion, and infarct size. In addition, there are multiple unanswered questions that require further investigation, in particular, questions as to which patients are best treated with thrombolysis. One of the most important predictors of clinical success is time to treatment, with early treatment of <3 hours for intravenous tissue plasminogen activator and <6 hours for intra-arterial thrombolysis demonstrating significant improvement in terms of 90-day clinical outcome and reduced cerebral hemorrhage. It is possible that improved imaging that identifies the ischemic penumbra and distinguishes it from irreversibly infarcted tissue will more accurately select patients for therapy than duration of symptoms. There are additional problems in the assessment of patients eligible for thrombolysis. These include being able to predict whether a particular site of occlusion can be successfully revascularized, predict an individual patient's prognosis and outcome after revascularization, and in particular, to predict the development of intracerebral hemorrhage, with and without clinical deterioration. It is not clear to assume that achieving immediate flow restoration due to thrombolytic therapy implies clinical success and improved outcome. There is no simple correlation between recanalization and observed clinical benefit in all ischemic stroke patients, because other interactive variables, such as collateral circulation, the ischemic penumbra, lesion location and extent, time to treatment, and hemorrhagic conversion, are all interrelated to outcome.This article was written under the auspices of the Technology Assessment Committees for both the American Society of Interventional and Therapeutic Neuroradiology and the Society of Interventional Radiology. The purpose of this document is to provide guidance for the ongoing study design of trials of intra-arterial cerebral thrombolysis in acute ischemic stroke. It serves as a background for the intra-arterial thrombolytic trials in North America and Europe, discusses limitations of thrombolytic therapy, defines predictors for success, and offers the rationale for the different considerations that might be important during the design of a clinical trial for intra-arterial thrombolysis in acute stroke. Included in this guidance document are suggestions for uniform reporting standards for such trials. These definitions and standards are mainly intended for research trials; however, they should also be helpful in clinical practice and applicable to all publications. This article serves to standardize reporting terminology and includes pretreatment assessment, neurologic evaluation with the NIH Stroke Scale score, imaging evaluation, occlusion sites, perfusion grades, follow-up imaging studies, and neurologic assessments. Moreover, previously used and established definitions for patient selection, outcome assessment, and data analysis are provided, with some possible variations on specific end points. This document is therefore targeted to help an investigator to critically review the scales and scores used previously in stroke trials. This article also seeks to standardize patient selection for treatment based on neurologic condition at presentation, baseline imaging studies, and utilization of standardized inclusion/exclusion criteria. It defines outcomes from therapy in phase I, II, and III studies. Statistical approaches are presented for analyzing outcomes from prospective, randomized trials with both primary and secondary variable analysis. A discussion on techniques for angiography, intra-arterial thrombolysis, anticoagulation, adjuvant therapy, and patient management after therapy is given, as well as recommendations for posttreatment evaluation, duration of follow-up, and reporting of disability outcomes. Imaging assessment before and after treatment is given. In the past, noncontrast CT brain scans were used as the initial screening examination of choice to exclude cerebral hemorrhage. However, it is now possible to quantify the volume of early infarct by using contiguous, discrete (nonhelical) images of 5 mm. In addition, CT angiography by helical scanning and 100 mL of intravenous contrast agent can be used expeditiously to obtain excellent vascular anatomy, define the occlusion site, obtain 2D and 3D reformatted vascular images, grade collateral blood flow, and perform tissue-perfusion studies to define transit times of a contrast bolus through specific tissue beds and regions of interest in the brain. Dynamic CT perfusion scans to assess the whole dynamics of a contrast agent transit curve can now be routinely obtained at many hospitals involved in these studies. The rationale, current status of this technology, and potential use in future clinical trials are given. Many hospitals are also performing MR brain studies at baseline in addition to, or instead of, CT scans. MRI has a high sensitivity and specificity for the diagnosis of ischemic stroke in the first several hours from symptom onset, identifies arterial occlusions, and characterizes ischemic pathology noninvasively. Case series have demonstrated and characterized the early detection of intraparenchymal hemorrhage and subarachnoid hemorrhage by MRI. Echo planar images, used for diffusion MRI and, in particular, perfusion MRI are inherently sensitive for the susceptibility changes caused by intraparenchymal blood products. Consequently, MRI has replaced CT to rule out acute hemorrhage in some centers. The rationale and the potential uses of MR scanning are provided. In addition to established criteria, technology is continuously evolving, and imaging techniques have been introduced that offer new insights into the pathophysiology of acute ischemic stroke. For example, a better patient stratification might be possible if CT and/or MRI brain scans are used not only as exclusion criteria but also to provide individual inclusion and exclusion criteria based on tissue physiology. Imaging techniques might also be used as a surrogate outcome measure in future thrombolytic trials. The context of a controlled study is the best environment to validate emerging imaging and treatment techniques. The final section details reporting standards for complications and adverse outcomes; defines serious adverse events, adverse events, and unanticipated adverse events; and describes severity of complications and their relation to treatment groups. Recommendations are made regarding comparing treatment groups, randomization and blinding, intention-to-treat analysis, quality-of-life analysis, and efficacy analysis. This document concludes with an analysis of general costs associated with therapy, a discussion regarding entry criteria, outcome measures, and the variability of assessment of the different stroke scales currently used in the literature is also featured.In summary, this article serves to provide a more uniform set of criteria for clinical trials and reporting outcomes used in designing stroke trials involving intra-arterial thrombolytic agents, either alone or in combination with other therapies. It is anticipated that by having a more uniform set of reporting standards, more meaningful analysis of the data and the literature will be able to be achieved." @default.
• W2155681330 created "2016-06-24" @default.
• W2155681330 creator A5028127034 @default.
• W2155681330 creator A5030596318 @default.
• W2155681330 creator A5031746458 @default.
• W2155681330 creator A5035503555 @default.
• W2155681330 creator A5042671764 @default.
• W2155681330 creator A5047486922 @default.
• W2155681330 creator A5067201014 @default.
• W2155681330 creator A5069989341 @default.
• W2155681330 creator A5077514596 @default.
• W2155681330 creator A5083232394 @default.
• W2155681330 creator A5088522170 @default.
• W2155681330 date "2003-08-01" @default.
• W2155681330 modified "2023-10-10" @default.
• W2155681330 title "Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke" @default.
• W2155681330 cites W1968324224 @default.
• W2155681330 cites W1969177537 @default.
• W2155681330 cites W1974125693 @default.
• W2155681330 cites W1986239469 @default.
• W2155681330 cites W1988631838 @default.
• W2155681330 cites W1994409747 @default.
• W2155681330 cites W2000473513 @default.
• W2155681330 cites W2003550028 @default.
• W2155681330 cites W2004314403 @default.
• W2155681330 cites W2006336793 @default.
• W2155681330 cites W2006440647 @default.
• W2155681330 cites W2007486075 @default.
• W2155681330 cites W2026402885 @default.
• W2155681330 cites W2034646969 @default.
• W2155681330 cites W2035023461 @default.
• W2155681330 cites W2037049476 @default.
• W2155681330 cites W2038172542 @default.
• W2155681330 cites W2042267799 @default.
• W2155681330 cites W2050188772 @default.
• W2155681330 cites W2059814844 @default.
• W2155681330 cites W2059864379 @default.
• W2155681330 cites W2067739098 @default.
• W2155681330 cites W2071686284 @default.
• W2155681330 cites W2071984852 @default.
• W2155681330 cites W2083268271 @default.
• W2155681330 cites W2085009848 @default.
• W2155681330 cites W2089151672 @default.
• W2155681330 cites W2096032435 @default.
• W2155681330 cites W2098032054 @default.
• W2155681330 cites W2099706007 @default.
• W2155681330 cites W2106568404 @default.
• W2155681330 cites W2116977361 @default.
• W2155681330 cites W2125955807 @default.
• W2155681330 cites W2128797504 @default.
• W2155681330 cites W2144601375 @default.
• W2155681330 cites W2148656951 @default.
• W2155681330 cites W2169162346 @default.
• W2155681330 cites W2266337156 @default.
• W2155681330 cites W2292308933 @default.
• W2155681330 cites W2478734695 @default.
• W2155681330 cites W2895973594 @default.
• W2155681330 cites W4232990983 @default.
• W2155681330 cites W4235858444 @default.
• W2155681330 cites W4250735710 @default.
• W2155681330 cites W4254273684 @default.
• W2155681330 cites W4292339830 @default.
• W2155681330 doi "https://doi.org/10.1161/01.str.0000082721.62796.09" @default.
• W2155681330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12869717" @default.
• W2155681330 hasPublicationYear "2003" @default.
• W2155681330 type Work @default.
• W2155681330 sameAs 2155681330 @default.
• W2155681330 citedByCount "1163" @default.
• W2155681330 countsByYear W21556813302012 @default.
• W2155681330 countsByYear W21556813302013 @default.
• W2155681330 countsByYear W21556813302014 @default.
• W2155681330 countsByYear W21556813302015 @default.
• W2155681330 countsByYear W21556813302016 @default.
• W2155681330 countsByYear W21556813302017 @default.
• W2155681330 countsByYear W21556813302018 @default.
• W2155681330 countsByYear W21556813302019 @default.
• W2155681330 countsByYear W21556813302020 @default.
• W2155681330 countsByYear W21556813302021 @default.
• W2155681330 countsByYear W21556813302022 @default.
• W2155681330 countsByYear W21556813302023 @default.
• W2155681330 crossrefType "journal-article" @default.
• W2155681330 hasAuthorship W2155681330A5028127034 @default.
• W2155681330 hasAuthorship W2155681330A5030596318 @default.
• W2155681330 hasAuthorship W2155681330A5031746458 @default.
• W2155681330 hasAuthorship W2155681330A5035503555 @default.
• W2155681330 hasAuthorship W2155681330A5042671764 @default.
• W2155681330 hasAuthorship W2155681330A5047486922 @default.
• W2155681330 hasAuthorship W2155681330A5067201014 @default.
• W2155681330 hasAuthorship W2155681330A5069989341 @default.
• W2155681330 hasAuthorship W2155681330A5077514596 @default.
• W2155681330 hasAuthorship W2155681330A5083232394 @default.
• W2155681330 hasAuthorship W2155681330A5088522170 @default.
• W2155681330 hasBestOaLocation W21556813301 @default.
• W2155681330 hasConcept C126322002 @default.
• W2155681330 hasConcept C127413603 @default.
• W2155681330 hasConcept C164705383 @default.
• W2155681330 hasConcept C2779581417 @default.
• W2155681330 hasConcept C2780645631 @default.
• W2155681330 hasConcept C3020199598 @default.
• W2155681330 hasConcept C500558357 @default.

• next